FDAnews
www.fdanews.com/articles/132583-subgroup-analysis-suggests-benefit-from-afatinib-in-some-lung-cancer-patients

Subgroup Analysis Suggests Benefit From Afatinib in Some Lung Cancer Patients

December 9, 2010
New data … show that afatinib leads to a significant four-fold extension (4.4 months vs. 1 month for placebo) in progression-free survival — the time before a tumour starts to grow again — for lung cancer patients most likely to have an epidermal growth factor receptor (EGFR) mutation.
iStockAnalyst